Infliximab in the treatment of patients with severe COVID-19 (INFLIXCOVID): protocol for a randomised, controlled, multicentre, open-label phase II clinical study

Infliximab in the treatment of patients with severe COVID-19 (INFLIXCOVID): protocol for a randomised, controlled, multicentre, open-label phase II clinical study

Abstract Background Despite the intense global research endeavour to improve the treatment of patients with COVID-19, the current therapy remains insufficient, resulting in persisting high mortality. Severe cases are characterised by a systemic inflammatory reaction driven by the release of pro-infl...

Full description

Bibliographic Details
Main Authors: Sina M. Coldewey, Charles Neu, Frank Bloos, Philipp Baumbach, Ulrike Schumacher, Michael Bauer, Philipp Reuken, Andreas Stallmach
Format: Article
Language:English
Published: BMC 2022-09-01
Series:Trials
Subjects:
COVID-19
Infectious diseases
Respiratory infections
Molecular diagnostics
Randomised controlled trial
Online Access:https://doi.org/10.1186/s13063-022-06566-5

Internet

https://doi.org/10.1186/s13063-022-06566-5

Similar Items